奥翔药业(603229) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 300,914,417.10, representing a year-on-year increase of 14.61%[4] - The net profit attributable to shareholders for the same period was CNY 112,480,834.45, reflecting a growth of 20.08% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 108,489,854.53, which is an increase of 17.69% year-on-year[4] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.19, marking an increase of 18.75%[4] - Total operating revenue for Q1 2024 reached ¥300,914,417.10, a 14.6% increase from ¥262,549,690.48 in Q1 2023[17] - Net profit attributable to shareholders for Q1 2024 was ¥112,480,834.45, representing a 20% increase compared to ¥93,672,808.45 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both ¥0.19, up from ¥0.16 in Q1 2023[18] Cash Flow - The net cash flow from operating activities decreased by 39.98%, primarily due to a relative reduction in received payments compared to the same period last year[7] - Cash flow from operating activities in Q1 2024 was ¥166,699,040.56, down from ¥208,507,860.64 in Q1 2023, indicating a decrease of 20.1%[19] - The net cash flow from operating activities for Q1 2024 was ¥26,983,529.17, a decrease of 40% compared to ¥44,955,913.77 in Q1 2023[20] - The total cash inflow from financing activities was ¥70,000,000.00, significantly lower than ¥573,933,781.92 in the previous year[21] - The net cash flow from investing activities was -¥21,275,021.86, compared to -¥81,121,541.50 in Q1 2023, indicating a reduced outflow[20] - The total cash outflow for operating activities was ¥179,967,435.29, compared to ¥243,010,208.91 in the previous year, showing a decrease in cash expenses[20] - The company experienced a negative impact of -¥691,997.96 from exchange rate fluctuations on cash and cash equivalents[21] - The net increase in cash and cash equivalents for Q1 2024 was -¥14,742,889.83, contrasting sharply with an increase of ¥501,884,558.67 in Q1 2023[21] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 3,045,057,290.07, up 3.17% from the end of the previous year[5] - The company's current assets totaled RMB 1,762,690,515.89, up from RMB 1,674,726,430.55, indicating an increase of about 5.2%[12] - Accounts receivable rose significantly to RMB 291,549,334.69 from RMB 132,750,843.88, representing an increase of approximately 119.9%[12] - Inventory decreased to RMB 311,211,637.19 from RMB 365,179,023.26, showing a decline of about 14.8%[12] - The company's total liabilities were not explicitly stated, but current liabilities included short-term borrowings of RMB 300,361,549.62, which remained relatively stable compared to RMB 300,259,888.90[13] - Total liabilities as of Q1 2024 amounted to ¥781,236,851.23, a decrease from ¥809,994,635.36 in the previous year[14] - The company’s non-current assets totaled RMB 1,282,366,774.18, a slight increase from RMB 1,276,844,758.91, reflecting a growth of about 0.4%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,488[9] - There were no significant changes reported in the top 10 shareholders or their shareholdings during the reporting period[10] Expenses and Other Financial Metrics - Operating costs for Q1 2024 were ¥167,168,222.81, up 10.9% from ¥150,656,558.62 in Q1 2023[17] - Research and development expenses for Q1 2024 were ¥23,250,646.98, an increase of 8.3% from ¥21,462,162.83 in Q1 2023[17] - The company reported a credit impairment loss of ¥7,737,852.29 in Q1 2024, compared to ¥2,691,497.15 in Q1 2023, indicating a significant increase in credit risk[17] - Deferred income tax liabilities rose to ¥2,659,507.82 in Q1 2024 from ¥2,073,627.22 in Q1 2023, showing an increase of 28.2%[14] - The company paid ¥62,363,523.90 in employee compensation, which is an increase from ¥59,126,401.00 in Q1 2023[20]